China's obesity drug pipeline surges: 47 firms, 67 candidates

A Global Data report reveals 47 Chinese companies are developing 67 clinical obesity drug candidates, signaling a major expansion in China's metabolic disease R&D. This reflects a strategic push to capture domestic and global market share in the high-growth GLP-1 segment, though most candidates are in early stages and regulatory approval remains uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works